Preventive Cardiovascular Care in Patients With HIV Infection in an Outpatient Clinic.
J Pharm Pract
; 35(4): 612-616, 2022 Aug.
Article
em En
| MEDLINE
| ID: mdl-33736523
BACKGROUND: People/patients living with human immunodeficiency virus (PLWH) are at an increased risk for atherosclerotic cardiovascular disease due to normal disease processes, antiretroviral medication adverse effects, and age-related comorbid conditions. Preventive cardiovascular (CV) screenings such as the need for statin, low-dose aspirin, or smoking cessation counseling are not well studied in PLWH. OBJECTIVES: To investigate whether there are differences in preventive CV care offered to patients with and without human immunodeficiency virus (HIV) infection in 1 outpatient clinic. METHODS: This retrospective study enrolled 150 consecutive patients if they had at least 4 appointments in 2 years and they did not have a history and they do not have a history of CV events. A randomly selected sample of patients without HIV infection receiving primary care services in the same clinic were used as the control group and were enrolled using the same inclusion criteria. RESULTS: More patients met statin criteria and were prescribed it in the HIV-negative arm [(70% vs. 24.67%; p < 0.0001); (89.52% vs. 54.05%; p < 0.0001)]. More patients in the HIV-negative arm met aspirin criteria and were prescribed it [(10.67% vs. 8.16%; p = 0.46); (50% vs. 33.3%; p = 0.33)]. There were more current smokers in the HIV-positive arm and a slightly greater number that received smoking cessation counseling [(38% vs. 11.33%; p < 0.0001); (82.46% vs. 76.47%; p = 0.58)]. CONCLUSION: Our results found that PLWH receive less preventive CV care compared to non-HIV-infected patients in the same outpatient clinic. Increased efforts are needed to ensure PLWH are receiving primary preventive CV care they need.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
Inibidores de Hidroximetilglutaril-CoA Redutases
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
J Pharm Pract
Assunto da revista:
FARMACIA
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos